Table 2.
Citation analysis of papers on anti-PD1/PDL1 immunotherapy published in major journals between 2010 and 2020.
| Journal | Total number of top-cited papers | Total number of papers | Average number of citations per paper | H-index | Percentage of top-cited papers |
|---|---|---|---|---|---|
| N. Engl. J. Med. | 40 | 61 | 1,558.3 | 51 | 65.6% |
| Lancet Oncol. | 23 | 130 | 200.9 | 73 | 17.7% |
| J. Clin. Oncol. | 18 | 164 | 171.6 | 83 | 11.0% |
| Lancet | 16 | 30 | 683.9 | 28 | 53.3% |
| JAMA Oncol. | 2 | 95 | 100.4 | 53 | 2.1% |
| JAMA | 1 | 3 | 259 | 3 | 33.3% |
| Total | 100 | 488 | 369.2 | 176 | 20.5% |
PD1, programmed cell death 1; PDL1, programmed cell death 1 ligand 1; H-index, Hirsch-index; Engl. J. Med., New England Journal of Medicine; JAMA, Journal of the American Medical Association; JAMA Oncol., JAMA Oncology; J. Clin. Oncol., Journal of Clinical Oncology; Lancet Oncol., Lancet Oncology.